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Summary Pyoderma gangrenosum (PG) is an autoinflammatory neutrophilic dermatosis char-
acterized by rapidly enlarging, painful ulcers. Anakinra is a recombinant interleukin
(IL)-1 receptor antagonist that blocks the activity of IL-1a and IL-1b by competi-
tively inhibiting IL-1 binding to the IL-1 type 1 receptor. We present a series of two
patients with recalcitrant PG, who had limited therapeutic options and multiple
comorbidities and multiple previous treatment failures, who obtained 100% healing
with anakinra. Compared with conventional first-line therapies for PG, the safety
profile of anakinra may be preferable for patients with multiple comorbidities. Fur-
ther research is needed to assess the safety and efficacy of anakinra for PG.
Pyoderma gangrenosum (PG) is an autoinflammatory
neutrophilic dermatosis characterized by rapidly enlarg-
ing, painful ulcers.1 Half of patients with PG have an
underlying inflammatory disease.2 Anakinra is a recom-
binant interleukin (IL)-1 receptor antagonist that blocks
the activity of IL-1a and IL-1b.3 We present a series of
two patients treated with anakinra for recalcitrant PG.
Report
Patient 1, a 51-year-old woman with a history of obesity,
was referred with painful inframammary and inguinal
ulceration (Fig. 1a,b). Skin biopsy showed neutrophilic
infiltration of the epidermis, consistent with PG. Haema-
tological investigations detected positive lupus anticoagu-
lant, b2-glycoprotein and anticardiolipin antibodies,
consistent with antiphospholipid syndrome, in the con-
text of three previous miscarriages. There was no family
history of neutrophilic dermatoses.
Therapy with prednisolone 80 mg produced rapid
clinical improvement. However, relapse occurred with
minimal reduction in dosage. Ciclosporin provided
modest effect, but had to be withdrawn after 1 month
due to nephrotoxicity. Infliximab was stopped follow-
ing secondary failure. Complications related to these
therapies had included recurrent herpes zoster,
multidrug-resistant urinary tract infections and
steroid-induced diabetes mellitus.
Inpatient hospital admission was required for intra-
venous methylprednisolone, followed by intravenous
immunoglobulin (IVIG) and rituximab infusions,
which delivered significant benefit for almost 1 year.
At that time, the disease relapsed severely, and ritux-
imab and IVIG were stopped.
Mycophenolate mofetil and doxycycline were then
trialled with minimal effect. The patient’s quality of life
had deteriorated substantially and she required
assisted accommodation because of immobility. Owing
to progressive disease with an associated renal injury
requiring dialysis, further inpatient admission was
required for intravenous methylprednisolone. Efficacy
was achieved with oral cyclophosphamide but this
was stopped after 9 months due to nausea and con-
cerns about long-term safety.
Given the patient’s history of treatment-resistant dis-
ease, therapy with anakinra was initiated, with
4 weeks of loading at 2 mg/kg daily, followed by
100 mg once daily. This agent had a rapid and pro-
found effect on symptoms, with 100% healing after
4 months of treatment. Clinical improvement facili-
tated a slow withdrawal of prednisolone after 4 years
of continuous oral steroid therapy. The patient’s
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iatrogenic diabetes requiring insulin has reversed and
she is now off all diabetic medication. She intention-
ally lost 22 kg in the first 4 months of treatment. Her
PG remains in remission, 24 months following initia-
tion of IL-1 blockade.
Patient 2 was a 67-year-old woman who was referred
with severe painful ulceration on her legs (Fig. 1c). She
was on adalimumab and methotrexate for rheumatoid
arthritis (RA). She also had a history of chronic kidney
disease, hypertension, peripheral vascular disease and
dyslipidaemia. Oral prednisolone 45 mg daily was
started with good initial effect; however, the following
month, the patient was admitted to the hospital with an
upper gastrointestinal (GI) bleed. Upper GI endoscopy
showed gastric and duodenal ulceration, and the
patient was placed on a protein pump inhibitor (PPI).
Second-line therapeutic strategies were limited by the
patient’s multiple comorbidities, and there was concern
about prescribing ciclosporin given her pre-existing
renal disease. The patient declined infliximab infusions
because she was unable to access regular transport to
hospital. Owing to the patient’s severe disease, her mul-
tiple comorbidities and the fact that anakinra is licensed
for RA, anakinra was introduced, and adalimumab and
methotrexate were stopped. Her PG slowly stabilized,
with 50% reduction in ulcer size after 6 months and
100% healing after 12 months. Repeat upper GI endo-
scopy showed healing of the peptic ulcers following
2 months of PPI therapy. Oral prednisolone was tapered
to stop over 8 months. Both the PG and RA remain qui-
escent 24 months following initiation of IL-1 blockade.
PG is a rare disease with an incompletely understood
aetiology.1 A 2018 Delphi consensus provided updated
diagnostic criteria for PG.4 Misdiagnosis is frequent and
associated conditions often go undetected.2 Treatment
of PG remains largely anecdotal, with only two pub-
lished randomized controlled trials.5,6 With no national
or international guidelines, management is challenging.
Treatment choice is based on the severity and extent of
PG and patient comorbidities.2 Up to 30% of patients
with PG have underlying inflammatory bowel disease
(IBD), higher than the rate of 20% in the UK population
reported by Langan et al.7 Pustular and peristomal vari-
ants of PG are more commonly seen in patients who
also have IBD. Inflammatory arthritis is present in
approximately 10% of patients. Solid organ malignancy
is seen in 5% of patients, while haematological malig-
nancy is present in < 5% and is more frequently associ-
ated with the bullous variant. PG can be seen in up to
15% of patients with antiphospholipid syndrome, with
localized thrombosis thought to precipitate the sec-
ondary inflammatory reaction.8 Other conditions such
as cryoglobulinaemia are only rarely associated with
PG. A three-fold increased risk of premature death has
been identified in patients with PG in the UK.7
Currently, PG is considered a neutrophil-mediated
autoinflammatory disease, involving aberrant activa-
tion of the inflammasome. This is supported by recent
studies that have provided novel insight into innate
immune system mutations and upregulation of the
Janus kinase signalling pathway in lesional skin. Other




Figure 1 (a,b) Patient 1: (a) multiple ulcerations with viola-
ceous undermined edges on the breast and inframammary
area; (b) extensive ulceration in the inguinal folds with slough.
(c) Patient 2: deep ulceration on the pretibial area with an
undermined violaceous edge and granulation tissue.
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system, and external triggers such as pathergy and
genetic predisposition. It is poorly understood how
these factors interact to influence the disease.
Several monogenic autoinflammatory diseases asso-
ciated with PG are caused by mutations in genes that
upregulate activity of IL-1, such as PSTPIP1,9 causing
PAPA syndrome (pyogenic arthritis, pyoderma gan-
grenosum and acne) and PASH syndrome (pyoderma
gangrenosum, acne and suppurative hidradenitis). The
PSTPIP1 mutant inhibits the anti-inflammatory effect
of pyrin, leading to release of proinflammatory cytoki-
nes such as IL-1b, IL-6, IL-8 and tumour necrosis fac-
tor (TNF)-a, further amplifying the inflammatory
response. These conditions respond favourably to IL-1
blockade, providing a theoretical basis for the use of
anakinra in nonsyndromic PG. Other case series have
highlighted the role of IL-1-driven inflammation in
autoimmune disease-associated PG.10
Our case series shows that excellent response to ana-
kinra is possible despite multiple previous drug failures.
Conventional first-line therapies for PG such as high-
dose corticosteroids, ciclosporin and TNF-a inhibition
may be problematic due to adverse events (AEs) in the
context of other inflammatory conditions or comorbidi-
ties. However, anakinra is associated with low rates of
serious AEs.3 Further research is needed to assess the
safety and efficacy of anakinra for nonsyndromic PG.
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Learning points
• PG is an autoinflammatory neutrophilic der-
matosis characterized by rapidly enlarging, pain-
ful ulcers.
• Half of patients with PG have an underlying
inflammatory disease; approximately 30% have
IBD, 10% have inflammatory arthritis, 5% have
haematological malignancy and 5% have solid
organ malignancy.
• Patients with PG in the UK have been shown to
have a three-fold increased risk of premature death.
• Several monogenic autoinflammatory diseases
associated with PG are caused by mutations in
genes that upregulate the activity of interleukin
(IL)-1, such as PSTPIP1, causing PAPA syndrome
and PASH syndrome.
• Anakinra is a recombinant IL-1 receptor antag-
onist that blocks the activity of IL-1a and IL-1b
by competitively inhibiting IL-1 binding to the IL-
1 type 1 receptor, which is expressed in a wide
variety of tissues and organs.
• The safety profile of anakinra may be preferable
to conventional treatments, such as corticosteroids
or ciclosporin, for patients with multiple comor-
bidities, but further research is needed to assess the
safety and efficacy of anakinra for PG.
References
1 Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a
review of pathogenesis and treatment. Expert Rev Clin
Immunol 2018; 14: 225–33.
2 Teagle A, Hargest R. Management of pyoderma
gangrenosum. J R Soc Med 2014; 107: 228–36.
3 Kullenberg T, L€ofqvist M, Leinonen M et al. Long-term
safety profile of anakinra in patients with severe
cryopyrin-associated periodic syndromes. Rheumatology
(Oxford) 2016; 55: 1499–506.
4 Maverakis E, Ma C, Shinkai K et al. Diagnostic criteria
of ulcerative pyoderma gangrenosum: a Delphi
consensus of international experts. JAMA Dermatol
2018; 154: 461–6.
5 Ormerod AD, Thomas KS, Craig FE et al. Comparison of
the two most commonly used treatments for pyoderma
gangrenosum: results of the STOP GAP randomised
controlled trial. BMJ 2015; 350: jh2958.
6 Brooklyn TN, Dunnill MG, Shetty A et al. Infliximab for
the treatment of pyoderma gangrenosum: a randomised,
double blind, placebo controlled trial. Gut 2006; 55:
505–9.
7 Langan SM, Groves RW, Card TR, Gulliford MC. Incidence,
mortality, and disease associations of pyoderma
gangrenosum in the United Kingdom: a retrospective
cohort study. J Invest Dermatol 2012; 132: 2166–70.
8 Ca~nas CA, Duran CE, Bravo JC et al. Leg ulcers in the
antiphospholipid syndrome may be considered as a form
of pyoderma gangrenosum and they respond favorably to
treatment with immunosuppression and anticoagulation.
Rheumatol Int 2010; 30: 1253–7.
9 Alavi A, French LE, Davis MD et al. Pyoderma
gangrenosum: an update on pathophysiology,
diagnosis and treatment. Am J Clin Dermatol 2017;
18: 355–72.
10 Beynon C, Chin MF, Hunasehally P et al. Successful
treatment of autoimmune disease-associated pyoderma
gangrenosum with the IL-1 receptor antagonist
anakinra: a case series of 3 patients. J Clin Rheumatol
2017; 23: 181–3.
Clinical and Experimental Dermatology 3ª 2021 The Authors. Clinical and Experimental Dermatology published by
John Wiley & Sons Ltd on behalf of British Association of Dermatologists
Anakinra for recalcitrant PG  C. O’Connor et al.
